These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 30209062)
1. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma. Zhao F; Evans K; Xiao C; DeVito N; Theivanthiran B; Holtzhausen A; Siska PJ; Blobe GC; Hanks BA Cancer Immunol Res; 2018 Dec; 6(12):1459-1471. PubMed ID: 30209062 [TBL] [Abstract][Full Text] [Related]
2. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Mariathasan S; Turley SJ; Nickles D; Castiglioni A; Yuen K; Wang Y; Kadel EE; Koeppen H; Astarita JL; Cubas R; Jhunjhunwala S; Banchereau R; Yang Y; Guan Y; Chalouni C; Ziai J; Şenbabaoğlu Y; Santoro S; Sheinson D; Hung J; Giltnane JM; Pierce AA; Mesh K; Lianoglou S; Riegler J; Carano RAD; Eriksson P; Höglund M; Somarriba L; Halligan DL; van der Heijden MS; Loriot Y; Rosenberg JE; Fong L; Mellman I; Chen DS; Green M; Derleth C; Fine GD; Hegde PS; Bourgon R; Powles T Nature; 2018 Feb; 554(7693):544-548. PubMed ID: 29443960 [TBL] [Abstract][Full Text] [Related]
3. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Mahoney KM; Freeman GJ; McDermott DF Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918 [TBL] [Abstract][Full Text] [Related]
4. Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma. Wu RY; Kong PF; Xia LP; Huang Y; Li ZL; Tang YY; Chen YH; Li X; Senthilkumar R; Zhang HL; Sun T; Xu XL; Yu Y; Mai J; Peng XD; Yang D; Zhou LH; Feng GK; Deng R; Zhu XF Clin Cancer Res; 2019 Jul; 25(14):4530-4541. PubMed ID: 30940655 [TBL] [Abstract][Full Text] [Related]
5. TGFβ Antagonizes IFNγ-Mediated Adaptive Immune Evasion via Activation of the AKT-Smad3-SHP1 Axis in Lung Adenocarcinoma. Ye F; Cai Z; Wang B; Zeng C; Xi Y; Hu S; Qu R; Yuan Z; Yue J; Tian Y; Wang X; Fu X; Li L Cancer Res; 2023 Jul; 83(13):2262-2277. PubMed ID: 37145144 [TBL] [Abstract][Full Text] [Related]
6. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767 [TBL] [Abstract][Full Text] [Related]
7. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade. Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156 [TBL] [Abstract][Full Text] [Related]
8. Response to BRAF inhibition in melanoma is enhanced when combined with immune checkpoint blockade. Cooper ZA; Juneja VR; Sage PT; Frederick DT; Piris A; Mitra D; Lo JA; Hodi FS; Freeman GJ; Bosenberg MW; McMahon M; Flaherty KT; Fisher DE; Sharpe AH; Wargo JA Cancer Immunol Res; 2014 Jul; 2(7):643-54. PubMed ID: 24903021 [TBL] [Abstract][Full Text] [Related]
10. PD-L1 Expression and Immune Escape in Melanoma Resistance to MAPK Inhibitors. Kakavand H; Rawson RV; Pupo GM; Yang JYH; Menzies AM; Carlino MS; Kefford RF; Howle JR; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA; Rizos H Clin Cancer Res; 2017 Oct; 23(20):6054-6061. PubMed ID: 28724663 [No Abstract] [Full Text] [Related]
11. Wnt Inhibition Sensitizes PD-L1 Blockade Therapy by Overcoming Bone Marrow-Derived Myofibroblasts-Mediated Immune Resistance in Tumors. Huang T; Li F; Cheng X; Wang J; Zhang W; Zhang B; Tang Y; Li Q; Zhou C; Tu S Front Immunol; 2021; 12():619209. PubMed ID: 33790893 [TBL] [Abstract][Full Text] [Related]
12. SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA. Wu R; Wang C; Li Z; Xiao J; Li C; Wang X; Kong P; Cao J; Huang F; Li Z; Huang Y; Chen Y; Li X; Yang D; Zhang H; Mai J; Feng G; Deng R; Zhu X J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33158915 [TBL] [Abstract][Full Text] [Related]
13. TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism. Canè S; Van Snick J; Uyttenhove C; Pilotte L; Van den Eynde BJ J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33637600 [TBL] [Abstract][Full Text] [Related]
14. Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGFβ enhance the efficacy of cancer immunotherapy. Ravi R; Noonan KA; Pham V; Bedi R; Zhavoronkov A; Ozerov IV; Makarev E; V Artemov A; Wysocki PT; Mehra R; Nimmagadda S; Marchionni L; Sidransky D; Borrello IM; Izumchenko E; Bedi A Nat Commun; 2018 Feb; 9(1):741. PubMed ID: 29467463 [TBL] [Abstract][Full Text] [Related]
15. Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1. Quach HT; Hou Z; Bellis RY; Saini JK; Amador-Molina A; Adusumilli PS; Xiong Y Expert Opin Investig Drugs; 2022 Nov; 31(11):1187-1202. PubMed ID: 36448335 [TBL] [Abstract][Full Text] [Related]
16. TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer. Principe DR; Park A; Dorman MJ; Kumar S; Viswakarma N; Rubin J; Torres C; McKinney R; Munshi HG; Grippo PJ; Rana A Mol Cancer Ther; 2019 Mar; 18(3):613-620. PubMed ID: 30587556 [TBL] [Abstract][Full Text] [Related]
17. Mechanisms of Drug Resistance in Melanoma. Winder M; Virós A Handb Exp Pharmacol; 2018; 249():91-108. PubMed ID: 28275910 [TBL] [Abstract][Full Text] [Related]
18. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855 [TBL] [Abstract][Full Text] [Related]
19. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Sandri S; Faião-Flores F; Tiago M; Pennacchi PC; Massaro RR; Alves-Fernandes DK; Berardinelli GN; Evangelista AF; de Lima Vazquez V; Reis RM; Maria-Engler SS Pharmacol Res; 2016 Sep; 111():523-533. PubMed ID: 27436149 [TBL] [Abstract][Full Text] [Related]
20. Advanced Melanoma: Resistance Mechanisms to Current Therapies. Haugh AM; Salama AKS; Johnson DB Hematol Oncol Clin North Am; 2021 Feb; 35(1):111-128. PubMed ID: 33759769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]